Safety and Preliminary Efficacy of Vorinostat With R-EPOCH in High-risk HIV-associated Non-Hodgkin’s Lymphoma (AMC-075)

We performed a phase I trial of vorinostat (VOR) given on days 1 to 5 with R-EPOCH (rituximab plus etoposide, prednisone, vincristine, cyclophosphamide, and doxorubicin hydrochloride) in patients with aggressive HIV-associated non-Hodgkin lymphoma. VOR was tolerable at 300 mg and seemingly efficacio...

Descripción completa

Detalles Bibliográficos
Autores principales: Ramos, Juan C., Sparano, Joseph A., Rudek, Michelle A., Moore, Page C., Cesarman, Ethel, Reid, Erin G., Henry, David, Ratner, Lee, Aboulafia, David, Lee, Jeanette Y., Ambinder, Richard F., Mitsuyasu, Ronald, Noy, Ariela
Formato: Online Artículo Texto
Lenguaje:English
Publicado: 2018
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6697160/
https://www.ncbi.nlm.nih.gov/pubmed/29426719
http://dx.doi.org/10.1016/j.clml.2018.01.004

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6697160/
https://www.ncbi.nlm.nih.gov/pubmed/29426719
http://dx.doi.org/10.1016/j.clml.2018.01.004

Ejemplares similares